The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke

Askiel Bruno, Valerie L. Durkalski, Christiana E. Hall, Rattan Juneja, William G. Barsan, Scott Janis, William J. Meurer, Amy Fansler, Karen C. Johnston

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Rationale: Patients with acute ischemic stroke and hyperglycemia have worse outcomes than those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be accomplished safely but has not been fully assessed for efficacy. Aims: The Stroke Hyperglycemia Insulin Network Effort trial aims to determine the safety and efficacy of standard vs. intensive glucose control with insulin in hyperglycemic acute ischemic stroke patients. Design: This is a randomized, blinded, multicenter, phase III trial of approximately 1400 hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood glucose range 80-179mg/dL, 4·44-9·93mmol/L) or continuous intravenous insulin (target blood glucose 80-130mg/dL, 4·44-7·21mmol/L) for up to 72h, starting within 12h of stroke symptom onset. The acute treatment phase is single blind (for the patients), but the final outcome assessment is double blind. The study is powered to detect a 7% absolute difference in favorable outcome at 90 days. Study outcomes: The primary outcome is a baseline severity adjusted 90-day modified Rankin Scale score, defined as 0, 0-1, or 0-2, if the baseline National Institutes of Health Stroke Scale score is 3-7, 8-14, or 15-22, respectively. The primary safety outcome is the rate of severe hypoglycemia (<40mg/dL, <2·22mmol/L). Discussion: This trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of intensive glucose control during acute stroke.

Original languageEnglish
Pages (from-to)246-251
Number of pages6
JournalInternational Journal of Stroke
Volume9
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Clinical Protocols
Hyperglycemia
Stroke
Insulin
Glucose
Blood Glucose
Patient Outcome Assessment
Safety
National Institutes of Health (U.S.)
Hypoglycemia
Outcome Assessment (Health Care)

Keywords

  • Acute ischemic stroke
  • Cerebral infarction
  • Clinical trial
  • Hyperglycemia
  • Protocols

ASJC Scopus subject areas

  • Neurology

Cite this

The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol : A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. / Bruno, Askiel; Durkalski, Valerie L.; Hall, Christiana E.; Juneja, Rattan; Barsan, William G.; Janis, Scott; Meurer, William J.; Fansler, Amy; Johnston, Karen C.

In: International Journal of Stroke, Vol. 9, No. 2, 02.2014, p. 246-251.

Research output: Contribution to journalArticle

Bruno, Askiel ; Durkalski, Valerie L. ; Hall, Christiana E. ; Juneja, Rattan ; Barsan, William G. ; Janis, Scott ; Meurer, William J. ; Fansler, Amy ; Johnston, Karen C. / The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol : A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. In: International Journal of Stroke. 2014 ; Vol. 9, No. 2. pp. 246-251.
@article{f27cddac2a4a4fa58ea81fae8d8b681e,
title = "The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke",
abstract = "Rationale: Patients with acute ischemic stroke and hyperglycemia have worse outcomes than those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be accomplished safely but has not been fully assessed for efficacy. Aims: The Stroke Hyperglycemia Insulin Network Effort trial aims to determine the safety and efficacy of standard vs. intensive glucose control with insulin in hyperglycemic acute ischemic stroke patients. Design: This is a randomized, blinded, multicenter, phase III trial of approximately 1400 hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood glucose range 80-179mg/dL, 4·44-9·93mmol/L) or continuous intravenous insulin (target blood glucose 80-130mg/dL, 4·44-7·21mmol/L) for up to 72h, starting within 12h of stroke symptom onset. The acute treatment phase is single blind (for the patients), but the final outcome assessment is double blind. The study is powered to detect a 7{\%} absolute difference in favorable outcome at 90 days. Study outcomes: The primary outcome is a baseline severity adjusted 90-day modified Rankin Scale score, defined as 0, 0-1, or 0-2, if the baseline National Institutes of Health Stroke Scale score is 3-7, 8-14, or 15-22, respectively. The primary safety outcome is the rate of severe hypoglycemia (<40mg/dL, <2·22mmol/L). Discussion: This trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of intensive glucose control during acute stroke.",
keywords = "Acute ischemic stroke, Cerebral infarction, Clinical trial, Hyperglycemia, Protocols",
author = "Askiel Bruno and Durkalski, {Valerie L.} and Hall, {Christiana E.} and Rattan Juneja and Barsan, {William G.} and Scott Janis and Meurer, {William J.} and Amy Fansler and Johnston, {Karen C.}",
year = "2014",
month = "2",
doi = "10.1111/ijs.12045",
language = "English",
volume = "9",
pages = "246--251",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol

T2 - A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke

AU - Bruno, Askiel

AU - Durkalski, Valerie L.

AU - Hall, Christiana E.

AU - Juneja, Rattan

AU - Barsan, William G.

AU - Janis, Scott

AU - Meurer, William J.

AU - Fansler, Amy

AU - Johnston, Karen C.

PY - 2014/2

Y1 - 2014/2

N2 - Rationale: Patients with acute ischemic stroke and hyperglycemia have worse outcomes than those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be accomplished safely but has not been fully assessed for efficacy. Aims: The Stroke Hyperglycemia Insulin Network Effort trial aims to determine the safety and efficacy of standard vs. intensive glucose control with insulin in hyperglycemic acute ischemic stroke patients. Design: This is a randomized, blinded, multicenter, phase III trial of approximately 1400 hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood glucose range 80-179mg/dL, 4·44-9·93mmol/L) or continuous intravenous insulin (target blood glucose 80-130mg/dL, 4·44-7·21mmol/L) for up to 72h, starting within 12h of stroke symptom onset. The acute treatment phase is single blind (for the patients), but the final outcome assessment is double blind. The study is powered to detect a 7% absolute difference in favorable outcome at 90 days. Study outcomes: The primary outcome is a baseline severity adjusted 90-day modified Rankin Scale score, defined as 0, 0-1, or 0-2, if the baseline National Institutes of Health Stroke Scale score is 3-7, 8-14, or 15-22, respectively. The primary safety outcome is the rate of severe hypoglycemia (<40mg/dL, <2·22mmol/L). Discussion: This trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of intensive glucose control during acute stroke.

AB - Rationale: Patients with acute ischemic stroke and hyperglycemia have worse outcomes than those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be accomplished safely but has not been fully assessed for efficacy. Aims: The Stroke Hyperglycemia Insulin Network Effort trial aims to determine the safety and efficacy of standard vs. intensive glucose control with insulin in hyperglycemic acute ischemic stroke patients. Design: This is a randomized, blinded, multicenter, phase III trial of approximately 1400 hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood glucose range 80-179mg/dL, 4·44-9·93mmol/L) or continuous intravenous insulin (target blood glucose 80-130mg/dL, 4·44-7·21mmol/L) for up to 72h, starting within 12h of stroke symptom onset. The acute treatment phase is single blind (for the patients), but the final outcome assessment is double blind. The study is powered to detect a 7% absolute difference in favorable outcome at 90 days. Study outcomes: The primary outcome is a baseline severity adjusted 90-day modified Rankin Scale score, defined as 0, 0-1, or 0-2, if the baseline National Institutes of Health Stroke Scale score is 3-7, 8-14, or 15-22, respectively. The primary safety outcome is the rate of severe hypoglycemia (<40mg/dL, <2·22mmol/L). Discussion: This trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of intensive glucose control during acute stroke.

KW - Acute ischemic stroke

KW - Cerebral infarction

KW - Clinical trial

KW - Hyperglycemia

KW - Protocols

UR - http://www.scopus.com/inward/record.url?scp=84892697797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892697797&partnerID=8YFLogxK

U2 - 10.1111/ijs.12045

DO - 10.1111/ijs.12045

M3 - Article

C2 - 23506245

AN - SCOPUS:84892697797

VL - 9

SP - 246

EP - 251

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 2

ER -